- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03520751
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
March 13, 2023 updated by: Zarife Sahenk, Nationwide Children's Hospital
Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)
This clinical trial is an open-label one-time injection dose study in which scAAV1.tMCK.NTF3 will be administered by intramuscular injections into muscles in both legs in CMT1A subjects with PMP22 gene duplication.
Three subjects ages 18 to 35 years receiving (8.87e11 vg/kg) will be enrolled.
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Detailed Description
This clinical trial is an open-label, one-time injection study in which scAAV1.tMCK.NTF3 will be administered by intramuscular injections into the medial and lateral heads of gastrocnemius, tibialis anterior, and rectus femoris muscles in both legs in CMT1A subjects with PMP22 gene duplication.
Three CMT1A patients, 18 to 35 years of age will be enrolled into one cohort in this trial.
These adult subjects will be enrolled at an effective dose (8.87e11 vg/kg) based on a qPCR titer using linearized standards, equivalent to 4.00x1012 vg/kg based on a qPCR titer using supercoiled standards) distributed bilaterally between both limbs in Cohort 1. Post-gene transfer monitoring will include follow up visits on days 7, 14, 30, 60, 90, 120, and months 6, 9, 12, 15, 18 and 24 following gene transfer.
Safety is the primary endpoint for this clinical gene transfer trial.
Stopping criteria are based on development of unacceptable toxicity defined as the occurrence of any one Grade III or higher, unanticipated, treatment-related toxicity.
The secondary endpoint is efficacy defined as halting of the decline in functional and sensory abilities measured by the CMT Pediatric Scale (CMTPedS) at 2 years post gene transfer.
The CMTPedS is an 11-item scale comprised of the Functional Dexterity Test, Nine-Hole Peg Test (9HPT), hand grip, foot plantar flexion, foot dorsiflexion, pinprick sensation, vibration sensation, the Bruininks Oseretsky Test- Balance assessment, gait assessment, long jump, and six-minute walk test (6MWT).
Exploratory outcome measures will include 10 meter run/walk timed test (10M), 100 meter timed test (100M), peroneal and ulnar CMAP amplitude and sensory and motor conduction velocities, a revised sensory testing to increase sensitivity for pinprick, touch-test and vibration assessments, visual analogue scales for pain and fatigue, Short Form Health Survey (SF-36) as Quality of Life measure, and circulating NT-3 levels.
Study Type
Interventional
Enrollment (Anticipated)
3
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects 18- 35 years old inclusive with CMT1A will be enrolled
- Must exhibit a 1.5 Mb duplication at 17p11.2 inclusive of the peripheral myelin protein 22 (PMP22) gene
- Males and females of any ethnic or racial group
- Must exhibit weakness of the ankle dorsiflexion muscle (but has full ROM against gravity and is able to stand on heels 3 seconds or greater)
- Abnormal nerve conduction velocities
- Ability to cooperate for clinical evaluation and repeat nerve conduction studies
- Willingness of sexually active subjects to practice a reliable method of contraception during the study
Exclusion Criteria:
- Active viral infection based on clinical observations or serological evidence of HIV, or Hepatitis B or C infection, herpesvirus or adenovirus
- Ongoing immunosuppressive therapy or immunosuppressive therapy within 6 months of starting the trial (e.g., corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin)
- Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
- Subjects with AAV1 binding antibody titers ≥ 1:50 as determined by ELISA immunoassay
- Subjects with circulating anti-NT-3 titers ≥ 1:50 as determined by ELISA immunoassay
- Treat with any investigational medication within 30 days before the infusion of study drug
- Abnormal laboratory values considered clinically significant (GGT > 3XULN, bilirubin ≥ 3.0 mg/dL, creatinine ≥ 1.8 mg/dL, Hgb < 8 or > 18 g/Dl; WBC > 15,000 per cmm)
- Any medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability
- Ankle contractures or surgeries preventing proper muscle strength testing
- Pregnancy or lactation (females subjects will be tested for pregnancy)
- Limb surgery in the past six months
- Severe infection (e.g. pneumonia, pyelonephritis, or meningitis) within 4 weeks before gene transfer visit (enrollment may be postponed)
- Anyone unwilling to disclose study participation with primary care physician and other medical providers.
- Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose (8.87e11 vg/kg)
Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
|
gene vector
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety based on number of participants with adverse events.
Time Frame: 2 years
|
AEs will be monitored and scored for severity and relatedness to the study article.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy - the ability to halt the decline in functional and sensory abilities
Time Frame: Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
CMT Pediatric Scale.
Efficacy will be defined as the ability to halt the decline in functional and sensory abilities as measured by the CMTPedS at 2 years post gene transfer.
This 11 item scale, developed by the Inherited Neuropathies Consortium, underwent validation testing in patients aged 3-20 years with CMT and generates a linear score of disability.
|
Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Physical Therapy Assessments The 100 Meter Timed Test (100m)
Time Frame: Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
The 100 Meter Timed Test will be an exploratory outcome for this study.
|
Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Electrophysiological testing
Time Frame: Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Measurement of ulnar sensory nerve amplitude and compound muscle action potential (CMAP); amplitude of the ulnar nerve (recorded from the abductor digiti minimi muscle) and the peroneal nerve (recorded from the tibialis anterior muscle) and sensory and motor conduction velocities.
|
Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Sensory testing using semi-quantitative Rydel Seiffer tuning fork, Semmes-Weinstein Monofilaments and Neurotips
Time Frame: Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Perceptions of touch pressure, pricking pain and vibration will be graded on the index finger and the great toe as normal (0), decreased (1), or absent (2).
In addition, the level of discrimination change for sensory modalities will be recorded in the dominant upper and lower limbs as normal (0), diminished or absent in fingers or toes (1), between fingers/toes and wrist or ankle (2), between wrist/ankle and mid-forearm or mid-calf level (3), between mid-forearm/mid-calf and elbow or knee (4) and above the level of elbow or knee (5).
|
Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Visual analog scale (VAS)
Time Frame: Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
The visual analog scale (VAS) of pain intensity consists of a line, most often 100 mm long, with 2 descriptors representing extremes of pain intensity (e.g., no pain and extreme pain) at each end.
Patients rate their pain intensity by making a mark somewhere on the line that represents their pain intensity and the VAS is scored by measuring the distance from the "no pain" end of the line.
|
Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
Short Form Health Survey (SF-36)
Time Frame: Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
The Short Form Health Survey (SF-36) will be used as a quality of life document to monitor and compare disease burden pre and post-treatment.
The SF-36 is a multi-purpose, short-form health survey with only 36 questions.
It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.
|
Screening, Day 90, 6 months, 1yr, 18 months, 2 yrs
|
NT-3 levels
Time Frame: Screening, Day 7-2 yrs
|
Circulating NT-3 levels will be measured by ELISA.
|
Screening, Day 7-2 yrs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Zarife Sahenk, MD., PhD., Nationwide Children's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2023
Primary Completion (Anticipated)
March 1, 2024
Study Completion (Anticipated)
July 1, 2024
Study Registration Dates
First Submitted
April 20, 2018
First Submitted That Met QC Criteria
April 27, 2018
First Posted (Actual)
May 11, 2018
Study Record Updates
Last Update Posted (Actual)
March 14, 2023
Last Update Submitted That Met QC Criteria
March 13, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Peripheral Nervous System Diseases
- Heredodegenerative Disorders, Nervous System
- Nervous System Malformations
- Polyneuropathies
- Nerve Compression Syndromes
- Charcot-Marie-Tooth Disease
- Hereditary Sensory and Motor Neuropathy
Other Study ID Numbers
- IRB17-01287
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Charcot-Marie-Tooth Neuropathy Type 1A
-
University Hospital, Clermont-FerrandCompletedCharcot-Marie-Tooth Type 1A NeuropathyFrance
-
University Hospital, Clermont-FerrandActive, not recruitingCharcot-Marie-Tooth Type 1A NeuropathyFrance
-
Hereditary Neuropathy FoundationRecruitingCharcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease, Type IA | Charcot-Marie-Tooth Disease Type 2A | Charcot-Marie-Tooth | Charcot-Marie-Tooth Disease, Type IB | Charcot-Marie-Tooth Disease Type 2 | Charcot-Marie-Tooth Disease, Type 2C | Charcot-Marie-Tooth Disease Type 2A2B | Charcot-Marie-Tooth... and other conditionsUnited States
-
Tasly GeneNet Pharmaceuticals Co., LtdRecruitingCharcot-Marie-Tooth Type 1AChina
-
Pharnext S.C.A.Premier Research Group plc; Eurofins Optimed; Synteract HCR (Syneos Health); Gr... and other collaboratorsActive, not recruitingCharcot-Marie-Tooth Disease, Type IAUnited States, Belgium, Canada, France, Netherlands, Spain, United Kingdom
-
MedDay Pharmaceuticals SACompletedCharcot-Marie-Tooth Disease | Peripheral Neuropathy | Chronic Inflammatory Demyelinating Polyneuropathy | Charcot-Marie-Tooth Disease Type 1A | Charcot-Marie-Tooth Disease, Type 1B | Anti-MAG NeuropathyFrance
-
Pharnext SACompletedCharcot-Marie-Tooth Disease | Hereditary Neuropathy With Liability to Pressure Palsies | Genetic DisordersFrance
-
University of GenovaUnknownCharcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease Type 1AItaly
-
University College, LondonUniversity of IowaUnknownCharcot-Marie-Tooth Disease, Type IA | Charcot-Marie-Tooth Disease Type 2A | Charcot-Marie-Tooth Disease, Type IB | Charcot-Marie-Tooth Disease, Type XUnited Kingdom
-
ENCellRecruitingCharcot-Marie-Tooth Disease Type 1AKorea, Republic of